Health Technology, Digital Healthcare

WellSky® Unveils Patient Engagement Platform to Personalize Condition Management and Optimize Health Outcomes

Businesswire | April 10, 2023 | Read time : 02:00 min

WellSky® Unveils Patient

WellSky, a leading health and community care technology company, today announced the launch of WellSky Patient, a transformative patient engagement platform aimed at identifying patient health risks, avoiding complications, and improving outcomes through stronger transparency and communication between patients, families, and clinical care teams.

A patient’s willingness and ability to participate in their care plans, particularly between provider visits, can greatly influence whether they experience new health problems and subsequent use of costly, unplanned emergent care. With the WellSky Patient platform, patients stay connected to their care providers between visits through two-way communication, video-based telehealth, and guided condition management programs. At the same time, patient-generated data from health status submissions and remote monitoring creates a comprehensive view for clinicians to track a patient’s progression and identify needs for clinical intervention.

“It is critical that our care team members have a complete picture of the patient’s condition and are given the insights necessary to engage most appropriately with the right resources at the right time,” said Dr. Bethany Snider, chief medical officer at Hosparus Health. “The capabilities WellSky is bringing to the table help give us the visibility we need to customize care to the individual, while also ensuring the patient’s family members and other caregivers are full participants in the care journey.”

When patients are given convenient and practical tools to help them take an active role in their own care and well-being, satisfaction is higher, complications are fewer, and outcomes are better. By focusing on the home as the center of patient engagement, healthcare organizations can gain new insights into patient behaviors and conditions, enabling them to adjust the plan of care, control costs, and positively influence outcomes to the benefit of the person and the healthcare organization alike.

“Patient engagement technology has historically focused on completing tasks related to a care episode, such as scheduling an appointment, completing an intake form, or viewing a lab result,” said Tim Ashe, chief clinical officer at WellSky. “That paradigm must shift toward the person, with a focus on how to best guide them through the care journey while surveying and managing their condition virtually. The innovation WellSky has developed to bring this strategy to life will be of great value to our clients, their care team members, and their patients.”

By putting the person at the center of their own care, healthcare organizations can offer unique and differentiated care experiences while gaining unprecedented insights into when – and how – specific interventions can optimize outcomes for patients and ultimately ensure success in models of value-based care.

About WellSky®

WellSky is one of America’s largest and most innovative healthcare technology companies leading the movement for intelligent, coordinated care. Our proven software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. In today’s value-based care environment, WellSky helps providers, payers, health systems, and community organizations scale processes, improve collaboration for growth, harness the power of data analytics, and achieve better outcomes by further connecting clinical and social care. WellSky serves more than 20,000 client sites — including the largest hospital systems, blood banks, cell therapy labs, home health and hospice franchises, post-acute providers, government agencies, and human services organizations. Informed by more than 40 years of providing software and expertise, WellSky anticipates clients’ needs and innovates relentlessly to build healthy, thriving communities.


Hear from the staff of Hospital Lauro Reus in Campo Bom, Brazil on how online training helped them adress the challenges faced in their radiology department due to the COVID-19 pandemic. They share how they used remote training to teach technicians the use of a new CT scanner and improve their overall workflow.


Hear from the staff of Hospital Lauro Reus in Campo Bom, Brazil on how online training helped them adress the challenges faced in their radiology department due to the COVID-19 pandemic. They share how they used remote training to teach technicians the use of a new CT scanner and improve their overall workflow.

Related News

Healthcare Analytics

Verily and OneOncology Announce Collaboration to Advance Cancer Research

businesswire | August 17, 2023

Verily, an Alphabet precision health technology company, and OneOncology, the national platform for independent oncology practices, have established a strategic partnership that will enable more efficient clinical trials. As part of the agreement, Verily will integrate its clinical trial management software (CTMS) platform, SignalPath, across practices in the OneOncology Research Network, OneR. SignalPath will enable sites to improve their systems infrastructure, streamline regulatory processes, and enhance collaboration with sponsors. “Clinical trial research is core to high-quality cancer care programs,” said Dr. Davey Daniel, Chief Medical Officer, OneOncology. “By using technology to create a platform offering from OneR, we can help enhance our partners’ clinical trial programs, which ultimately better democratizes clinical trials, and improves health equity.” SignalPath is the only CTMS that uses next-generation protocol digitization technology to configure and systematize study protocol workflows within the platform, saving site staff time and effort. It’s designed to improve the costs, complexities, and time associated with running clinical studies while optimizing for quality and time with patients. “Verily and OneOncology are both committed to transforming the experience for oncology practices participating in research with the latest data and technology,” said Dr. Brad Hirsch, Head of Product & Implementation at Verily and co-founder of SignalPath. “SignalPath delivers on that vision, easing the workflow for oncologists and their staff, so they can focus on delivering the best possible care.” This partnership aims to expand research opportunities across community oncology centers, offering the potential to increase access and participation in clinical trials for new cancer treatments. There are over 1,300 anticancer drugs in the development pipeline, but the participation rate in trials among adult cancer patients in the U.S. is only 6%. OneOncology will continue to partner with Verily as it further develops connected solutions across its research and care product offerings, including an oncology-focused longitudinal registry to advance cancer research. About Verily Verily is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. About OneOncology OneOncology was founded by community oncologists, for community oncologists, with the mission of improving the lives of everyone living with cancer. Our goal is to enable community oncology practices to remain independent and to improve patient access to care in their communities, all at a lower cost than in the hospital setting. OneOncology supports its platform of community oncology practices through group purchasing, operational optimization, practice growth, and clinical innovation. The partnership’s 960 cancer care providers care for approximately 528,000 patients at more than 300 sites of care nationwide.

Read More

Digital Healthcare, Healthcare Analytics

Equum Medical Launches the Lighthouse Series™: Inspiring Success Stories in Telehealth and Healthcare Transformation

PRNewswire | July 24, 2023

Evidence is mounting from the experiences of hospitals large and small, urban and rural that telehealth is having a positive effect on staffing, patient safety, clinical services and hospital revenue, Equum Medical reports. The company, a leading provider of innovative telehealth services, has released the Equum Medical Lighthouse Series™. These customer success stories showcase the transformative power of telehealth in addressing key challenges faced by health systems and hospitals worldwide. The Series is intended to highlight real-world examples of how a complete acute care telehealth service using remote physicians, nurses and monitoring technologists supplements current hospital staff, provides specialist expertise and quickly moves patients to the most appropriate sites for care. In today's rapidly evolving healthcare landscape, health systems and hospitals are constantly seeking innovative solutions to enhance efficiency, reduce costs and improve patient outcomes. The Equum Medical Lighthouse Series brings to the forefront some of the most pressing challenges faced by healthcare providers, including ED capacity, ICU mortality and length of stay, physician and nurse burnout, and rural hospital specialist access. Telehealth offers a promising solution by increasing access to care in underserved areas, alleviating the shortage of clinicians and reducing costs to make healthcare more accessible and affordable. Dr. Scurlock, CEO and Founder of Equum Medical, emphasized the importance of sharing these success stories: "We are thrilled to launch the Equum Medical Lighthouse Series. By showcasing real-world examples of how telehealth has successfully addressed critical challenges, we aim to encourage broader adoption of telehealth and the dissemination of information on successful strategies." The series aims to provide healthcare leaders with actionable insights and evidence-based strategies to navigate their own telehealth implementations by demonstrating the tangible benefits that can be achieved by embracing telehealth and leveraging its potential to drive positive change in healthcare delivery. Healthcare providers, administrators and industry professionals can gain a valuable resource for understanding the diverse applications of telehealth and the significant impact it can have on healthcare delivery, patient outcomes and the overall well-being of both patients and providers. "We are going to continue to grow the Lighthouse Series as we get additional results from our engagements," said Karsten Russell-Wood, MBA, MPH, Equum's Chief Marketing Officer. "We want this to be a resource for innovators and evidence of what our model of care can do to ease the pressure on hospitals and health systems in this time of profound change for our industry." Equum Medical is an active member of the American Telemedicine Association and the National Rural Health Association, through which participating hospital systems can access thought leadership and engage with Equum Medical executives to expand telehealth understanding and applications. About Equum Equum Medical is a nationally recognized, tech-enabled clinical services company that provides the people and processes that ensure investments in telehealth technology succeed in transforming inpatient care. Equum's clinical services platform focuses on the acute care population spanning ED, ICU, nursing and sitter solutions.

Read More

Healthcare Analytics

LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform

Globenewswire | August 01, 2023

LumiraDx Limited a next-generation point of care diagnostics company, today announced that it signed a commercial distribution agreement with Axon Lab AG (“Axonlab”) for the commercialization of its LumiraDx Platform and diagnostic tests to include exclusive distribution rights in Switzerland and additional non-exclusive distribution rights in further European countries to include and starting in Germany. Under the terms of the distribution agreement, LumiraDx has granted Axonlab the right to promote, market, and sell the LumiraDx Platform and tests to hospitals, doctors, clinics, private laboratories and research institutions in the aforementioned countries. The distribution agreement is effective immediately. LumiraDx will continue its direct sales programs in its many active markets across the globe. Axonlab has dedicated diagnostics franchises and direct offices in the countries covered under the distribution agreement and is well positioned to accelerate the commercial success of the LumiraDx Platform in Switzerland and Germany. "We are excited to partner with LumiraDx for the commercial distribution of the LumiraDx Platform in Switzerland and Germany,” said Lukas Hadorn CEO of Axonlab. “LumiraDx clearly has shown to have a unique technology with a broad, attractive menu of diagnostic rapid tests, on an intuitive and simple to use instrument, which allows these key tests to be performed in doctors’ offices, clinics, and other testing sites at the point-of-care. The LumiraDx Platform matches well into Axonlab’s broad portfolio of point-of-care diagnostic solutions. In addition to offering a diversified portfolio, Axonlab places great emphasis on partnership-based customer relationships. We respond individually to the needs of our customers and always strive to implement segment specific solutions that suit best for all parties involved.” David Walton, LumiraDx’s Chief Commercial Officer commented "We are pleased to announce our new partnership with Axonlab, whose track record has shown that they are a fantastic partner for us in these markets. With the new distribution agreement for Switzerland and Germany, the Axonlab collaboration adds two important markets to our distribution portfolio and will allow us to accelerate the commercial roll-out of our unique LumiraDx Platform. LumiraDx already has a strong commercial presence, either directly or through our distribution partners, and we plan to continue expanding this worldwide network through the addition of such major commercial partnerships.” About LumiraDx LumiraDx Limited is a next-generation point of care diagnostics company that is transforming community-based healthcare. Its actively controlled microfluidic technology provides fast, high performance and accessible diagnostic solutions wherever the patient is for nearly any testing scenario, creating unique testing options at the point of need. The company offers a broad menu of lab comparable tests on a single portable Platform, with more than 30 assays on the market and in various stages of development, covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. The company also supports high-complexity laboratory testing in an accessible high-throughput format to leverage current molecular laboratory operations. Founded in 2014 and based in the UK, LumiraDx's diagnostic testing solutions are being deployed globally by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to help screen, diagnose, and monitor wellness as well as disease. About Axonlab Axonlab is a proactive and reliable partner of hospitals, medical practices, private laboratories, research and industry, as well as of private individuals. It is a cutting-edge, customer-oriented service company operating in the fields of IVD, Life Science and Medical IT for the healthcare sector and is a leading company in the point-of-care solution business in Europe. The company collaborates with reputable international supply partners in selling innovative systems to clinics, doctors and the research sector. Axonlab is focused on providing a comprehensive, future-oriented service and to provide a foundation for long-term business relations. Axonlab’s purpose to contribute to improving healthcare for the people in Europe and to consequently contribute to patients’ quality of life is firmly anchored in the DNA of the company. Having been engaged with customers for more than 33 years is why they know and understand their customer’s requirements thoroughly.

Read More